http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2002540837-A

Outgoing Links

Predicate Object
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61F2009-0088
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61F2009-00893
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61F2009-00853
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61F2009-00882
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B2018-20359
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61F2009-00872
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61F9-008
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61F9-00804
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61F9-00806
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F9-01
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F9-008
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F9-007
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61B18-20
filingDate 2000-02-28-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationDate 2002-12-03-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber JP-2002540837-A
titleOfInvention Offset ablation profile for irregular astigmatism treatment
abstract Kind Code: A1 The present invention provides a custom-made, short-term ablation capability that can treat corneal abnormalities by ablating the refraction therapy profile in a laterally offset manner. These treatment profiles, when centered on the eye E, may be suitable for treating standard refractive errors such as myopia, hyperopia and cylindrical astigmatism. By selectively offsetting one or more ablation profiles at selected points across the corneal surface C, the laser system 14 allows the irregular astigmatism, quadrant corneal gradient, asymmetric astigmatism, previously applied refractive treatment ( (E.g., corneal incision, extracentral resection, asymmetric distortion due to corneal transplantation, keratoplasty in all layers, etc.), abnormal corneal growth, sporadic, bilateral keratoconus, etc. Refraction errors caused by corneal abnormalities such as sex astigmatism and irregularities can be reduced.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8503609-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8611497-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8837675-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8848869-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8787524-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8320524-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8457277-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8761336-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8923479-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9025727-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2009502289-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8630388-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9272161-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8855267-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8494116-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8363783-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8512236-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8295437-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2010506689-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8306186-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8506558-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-4918547-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8442185-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8995618-B2
priorityDate 1999-04-07-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID21910289
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID449779615
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID13743157
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID452367356

Total number of triples: 48.